Clinical Trial Update: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating LM-108 in combination with a PD-1–based therapy for patients with recurrent or metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• LM-108
• PD-1 inhibitor

Snippet

Sponsor: Fudan University | Conditions: TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING